|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, no effective targeted therapy has been developed for NRAS mutant tumors or in melanomas with as yet unknown driver mutations.
|
23420410 |
2013 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Isocitrate dehydrogenase 1 mutations in melanoma frequently co-occur with NRAS mutations.
|
30003571 |
2018 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, our findings show miRNA dysregulation in malignant melanoma and its relation to established molecular backgrounds of BRAF and NRAS oncogenic mutations.
|
20357817 |
2010 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
No mutations of the BRAF and NRAS genes were found in the melanoma.
|
19264228 |
2009 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
No significant differences in the distribution of BRAF or NRAS mutations could be found between melanoma and associated nevi or between melanoma associated nevi and control nevi.
|
23861977 |
2013 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the ras genes are key events in the process of carcinogenesis; in particular, point mutations in codon 61 of exon 2 of the N-ras gene occur frequently in cutaneous melanoma.
|
11886512 |
2001 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Melanoma onset and progression are associated with a high variety of activating mutations in the MAPK-pathway, most frequently involving BRAF (35-45%) and NRAS (15-25%) genes, but also c-KIT and PTEN.
|
31446019 |
2019 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In this study we observed a dominant role for the HGF/MET axis in mediating resistance to BRAF and MEK inhibitors in models of BRAFV600E and NRAS mutant melanoma.
|
28147313 |
2017 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We analyzed exons 1, 11, and 15 of the BRAF gene and exons 1 and 2 of the N-ras gene for mutations in 38 metastatic melanomas by PCR-single-strand conformation polymorphism and direct sequencing.
|
12960123 |
2003 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Whereas many studies have analyzed RAF and PI3K signaling in mutant NRAS melanoma, the role of RalGEF/Ral is understudied and TBK1 has not been examined.
|
24962318 |
2014 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
When compared to WT, multivariate analysis of melanoma-specific survival (MSS) identified NRAS mutations as an adverse prognostic factor [hazard ratio (HR) 2.96; P = 0.04] but not BRAF(V600E) mutations (HR 1.73; P = 0.23).
|
21615881 |
2011 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Selective MEK inhibitors have the ability to inhibit growth and induce cell death in BRAF- and NRAS-mutant melanoma cell lines.
|
28537004 |
2017 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
BRAF and NRAS mutations were more frequent in nodular and superficial spreading melanomas (P < 0.001).
|
25357015 |
2015 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
BRAF and NRAS mutations are predominant in melanoma and lead to overactivation of the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathways.
|
28543695 |
2017 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
N2/M2 lesions are characterized by inflammatory-type and AXL gene signatures with an equal distribution of wild-type and mutated BRAF and low prevalence of NRAS mutations in M2 melanomas.
|
29995873 |
2018 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, we tested the impact of a second NRAS mutation in 7 BRAF inhibitor resistant early passage cell cultures on the selection of second line therapies.We observed a rapid monophyletic evolution of melanoma subpopulations in response to targeted therapy that was not observed in non-targeted therapy.
|
27791198 |
2016 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Both the melanomas harbor KIT mutation in approximately 15% of the cases; BRAF or NRAS mutation is found in approximately 10-15% of acral melanoma, but these mutations are less frequent in mucosal melanoma.
|
30675668 |
2019 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In contrast the epithelial-like subtype of melanomas with wild-type N-RAS and B-RAF alleles displayed an effective G2 checkpoint but a significant defect in G1 checkpoint function.
|
17597816 |
2008 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
Mutations in NRAS were found in 5.2% of primary melanomas, 5.9% of nevi and no NRAS mutations were seen in in-situ melanomas.
|
16845322 |
2006 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
These preliminary results suggest that BRAF and NRAS mutation status should be determined in prospective phase II studies of HSP90 inhibitors in melanoma.
|
18375819 |
2008 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We screened 115 melanoma samples for the most common B-RAF and N-RAS mutations found in melanoma using a site-directed mutagenesis-based detection technique.
|
15737846 |
2005 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We sought to evaluate whether tumor genotype (e.g., NRAS mutations) correlates with benefit from immune therapy in melanoma.
|
25736262 |
2015 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
NRAS-mutant tumors tended to behave more aggressively particularly in early stages of the disease in this high-risk melanoma population.
|
28797232 |
2017 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Common oncogenic mutations in melanomas, in particular in BRAF (encoding p.Val600Glu) and NRAS (encoding p.Gln61Lys or p.Gln61Arg), were absent.
|
26343386 |
2015 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We have evaluated five real-time ARMS assays: BRAF 1799T>A, [this includes V600E and V600K] and NRAS 182A>G [Q61R] and 181C>A [Q61K] in melanoma, EGFR 2573T>G [L858R], 2235-2249del15 [E746-A750del] in non-small-cell lung cancer, and compared the results to DNA sequencing of the mutation 'hot-spots' in these genes in formalin-fixed paraffin-embedded tumour (FF-PET) DNA.
|
20925915 |
2010 |